Full-Time
Director Site Start Up
Precision for Medicine
1,001-5,000 employees
Global CRO for precision medicine trials
No salary listed
Remote in Australia
Remote
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to Precision for Medicine
See people who can refer or advise you
- A bachelor's degree in life sciences or a related field, or an equivalent combination of education, training, and experience.
- A minimum of 12 years of experience in clinical research, including extensive Site Start-up experience.
- Extensive leadership experience or demonstrated competencies for the position.
- Expert knowledge of Good Clinical Practice and International Council for Harmonisation guidelines and the clinical development process.
- A demonstrated leadership track record.
- Experience working in a team environment with resource management experience.
- Experience with Microsoft Office products, including Outlook, Word, Excel, and PowerPoint, and clinical software such as clinical trial management systems, electronic trial master files, and electronic data capture systems.
- Fluency in English.
- Provide the Site Start-up team with guidance, leadership, and overall support for project delivery, communication, human resources, revenue enhancement, procedures, systems, and processes to meet client and departmental targets.
- Support the overall management of Site Start-up delivery through direct management and cross-functional oversight of departments involved in submissions, site contracts, budget negotiations, and other start-up requirements.
- Work with the Head of Site Start Up to establish the Precision for Medicine Site Start-up framework, including intelligence, tools, methodology, risk evaluations, and mitigations.
- Support collaboration with Clinical Operations, project management, and other cross-functional departments in planning, execution, and governance of global and regional Site Start-up activities.
- Work with the Head of Site Start Up to support defined corporate and departmental business strategies.
- Act as an ambassador for change management as the global structure evolves for company growth and expansion.
- Provide leadership and oversight for Site Start-up programs, including large or increasingly complex programs.
- Manage escalations and remediate Site Start-up concerns in a timely and effective manner.
- Support process and delivery optimization to help Site Start-up teams meet or exceed budget targets.
- Partner with Global Resourcing teams to assess and manage Site Start-up leads, specialists, and site contract management staff against cost, time, and quality goals.
- Support Site Start-up team career development, growth, and succession planning, and ensure compliance with company policies and applicable regulatory guidelines.
- Support coordination of Site Start-up leads' participation in current and prospective client meetings and presentations.
- Collaborate with Business Development on opportunity development, proposals, budgeting, bid-defense preparation, and attendance for Site Start-up participants.
- Work with global and regional functional leaders to support Site Start-up project strategy and delivery.
- Support Site Start-up evaluations and implement required project changes.
- Develop, measure, and report Site Start-up key performance indicators and lead continuous improvement.
- Reinforce company culture and values to motivate the Site Start-up team, maintain engagement, and drive retention.
- Excellent communication and interpersonal skills to effectively interface with others in a team setting.
- Excellent organizational skills, attention to detail, and a customer-service demeanor.
- Proven experience in strategic planning, risk management, and change management.
Precision For Medicine is a global clinical research organization (CRO) that helps life sciences companies run clinical trials from early to regulatory approval. It specializes in precision medicine, focusing on oncology, cell and gene therapy, and rare diseases. The company combines clinical trial services with specialty laboratory work and data sciences to improve speed, reduce costs, and increase the likelihood of success in bringing therapies to patients. It differentiates itself by integrating advanced technologies and data-driven biostatistics with specialized labs to support end-to-end trials across all stages. Its goal is to enable faster, more cost-efficient development of targeted therapies that meet regulatory requirements and reach patients in need.
Company Size
1,001-5,000
Company Stage
Growth Equity (Venture Capital)
Total Funding
$225M
Headquarters
Chevy Chase, Maryland
Founded
2012
Get referred to Precision for Medicine
See people who can refer or advise you
Simplify's Take
What believers are saying
- Amanda Owens joined August 2026 to scale high-demand biospecimen solutions.
- Chris Clendening joined to push AI-driven specialty labs and biomarker workflows.
- Japan office and Singapore office expand access to Asia-Pacific trials and patients.
What critics are saying
- Blackstone is shopping Precision Medicine Group CRO assets in 2026, disrupting retention.
- S&P kept Precision at B- in August 2025, signaling heavy sponsor leverage.
- Trade-secret litigation with Blue Matter persists through March 2026, draining management attention.
What makes Precision for Medicine unique
- Triple former FDA oncology leaders give Precision rare regulatory muscle.
- Tokyo and Singapore offices deepen APAC trial execution in regulated markets.
- Biospecimen biobanks with 10 million specimens anchor integrated lab-clinical services.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
Disability Insurance
Parental Leave
Paid Sick Leave
Paid Vacation
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 6%Precision for Medicine has appointed Amanda Owens as General Manager, Biospecimen Solutions. She will lead the business's commercial and operational strategy as demand grows for deeply annotated biospecimens rich in genetic and molecular data. Owens brings extensive life sciences experience across biospecimen services, genomics, gene editing and advanced therapies. She previously held senior commercial leadership roles at Landmark Bio and Discovery Life Sciences. Precision for Medicine maintains biorepositories containing over one million biofluid specimens and three million tissue specimens. The company integrates clinical trial design and execution with laboratory expertise and data intelligence. Owens holds an MBA from the University of Alabama in Huntsville and advanced degrees in biological sciences. She is based in Nashville, Tennessee.
Amanda Owens leads Precision Medicine's biospecimen expansion. Shaking up the biospecimen game. Amanda Owens, a seasoned pro in the life sciences sector, is now in the driver's seat at Precision for Medicine, taking charge as General Manager of Biospecimen Solutions. This ain't just a fancy title; she's stepping into a role that's shaking up how biopharma taps into biospecimens for drug development. It's a bustling field, folks, because the demands are soaring - everyone wants more data, more accuracy, and more bang for their buck in research. The new frontier in drug development. What's the big fuss about biospecimens, you ask? Well, they're not your average samples snagged off a shelf. Investors Hangout, LLC is talking about specimens that pack a punch with genetic and molecular profiles, the very things pushing forward next-gen therapies. This is a scientific gold rush, and Owens is the guide who knows where to dig. Her track record spans from landmark roles at Discovery Life Sciences to steering commercial ships at Landmark Bio. If there's one thing this industry needs, it's someone who knows how to marry science with strategy - precisely what Owens brings to the table. Unpacking the leadship strategy. Owens steers toward strategic partnerships. If you think it's all about the samples, think again. Sofia Baig, the president over at Precision for Medicine, made it clear: matching the right sample to the right project is an art, not a mere transaction. That means diving deep into what the sponsors need and predicting how those needs morph over time. Precision has these massive stash houses of over a million biofluid specimens and three million tissue samples, so Owens gets to play with a helluva repertoire. "Quality and speed are not negotiable. It's about a comprehensive understanding," said Owens, emphasizing the teardown of transactional barriers. Consultative partnerships over transactions. This isn't just delivering goods. Precision's suite of lab capabilities enables them to dig plenty deeper than the surface level, crafting partnerships instead of simple hand-offs. It's a pivot toward consultative relationships rather than mere supplier-buyer exchanges. This is where the biz smarts meet scientific vigor, and Owens is poised to harness those dual strengths. The broader impact. Why investors should take notice. Here's the investor angle: what Owens' appointment means for the sector is a steady trajectory towards more integrated, technically sophisticated biospecimen solutions. It's a nod toward adding value in the pipeline - accelerating drug discovery translates into quicker revenue streams and perhaps lucrative partnerships or buyouts down the road. Stay tuned to the playbook Owens rolls out because it could be a game-changer in how the industry views biospecimen sourcing. Precision for Medicine's backing, with over 3,500 people spread internationally, serves as both an engine and a shield. Whether you're looking from the perspective of a startup in biotech or a solid player in pharma, these are the kinds of developments that shape strategic pivots and can push market momentum. Play your cards right, and Owens' blueprint might just become the one everyone else tries to imitate. Investors ought to watch how this strategic rolodex grows under her leadership.
Precision for Medicine has appointed laboratory industry veteran Chris Clendening as General Manager, Labs Translational Sciences. Reporting to President Sofia Baig, Clendening will oversee Precision's global specialty labs business, including operational delivery, growth strategy, and AI-driven approaches to accelerate biomarker research. Clendening most recently served as Senior Vice President of Biotechnology Operations and Product Development at Clario. He previously spent over a decade in executive leadership at PPD Central Labs, where he developed an evolutionary central laboratory platform that earned him the CenterWatch Award for Innovation. In his new role, Clendening will focus on global operational delivery and developing integrated scientific solutions for Precision's clients worldwide. He holds a Bachelor of Science in biology and chemistry from Muskingum University and is based in Cincinnati, Ohio.
Precision for Medicine has appointed Paz Vellanki, MD, PhD, as Vice President of Clinical Development, Oncology. Dr Vellanki previously served as Associate Director of the Division of Oncology 2 at the FDA, overseeing drug development for lung cancer, head and neck cancer and rare tumours. Her appointment completes a trio of former FDA oncology leaders at the company, joining Chief Medical Officer Harpreet Singh and Vice President Nicholas Richardson. During nearly seven years at the FDA, Dr Vellanki led the technical guidance on circulating tumour DNA for early-stage solid tumours and served on the Project Endpoint Working Group. The biomarker-driven clinical research organisation, part of Precision Medicine Group, operates across 40 locations globally with 3,500 staff.
RETECH-Madrid Community helps connect innovation with the real needs of the healthcare system. We interviewed the co-founders of eB2, best solution in the RETECH-Madrid Community health challenge. eB2 is a health startup that develops tools and solutions for patient care and monitoring using Artificial Intelligence and mobile technologies. eB2 is a platform applied to mental health, certified as a medical device, that allows continuous monitoring of patient behavior and transforms it into objective clinical indicators. The company has been recognized as the best solution for the health challenge defined by the company Precision for Medicine, at the II Innovation Forum of the RETECH-Madrid Community project. The meeting brought together over 50 ecosystem actors including startups, scaleups, and leading companies in Greentech, Health, and Aerospace at the SID building in Tres Cantos, with the aim of fostering business collaboration and addressing the real challenges of these three strategic sectors through technological solutions. We spoke with Ana Hernando Abascal, co-founder and CEO, and Antonio Artés Rodríguez, co-founder and CSO of Evidence-Based Behavior (eB2) about their startup's goals and their experience in the Digital Entrepreneurship Networks project in the Madrid Community. How would you define your solution in the health field and what needs does it address? eB2 (Evidence-Based Behavior) is an artificial intelligence platform applied to mental health, certified as a medical device, that allows continuous monitoring of patient behavior and transforms it into objective clinical indicators. It addresses a key need of the healthcare system: moving from a reactive model, based on occasional visits, to a preventive model capable of early detection of clinical deterioration. Today, professionals lack continuous and objective tools to anticipate relapses or crises. Our solution acts as a clinical co-pilot, helping professionals make more informed decisions and intervene earlier, improving care quality and system efficiency. Additionally, the platform is also used in clinical and academic research, enabling the generation of scientific evidence and development of new digital biomarkers based on longitudinal data. What does it mean for you to have been selected as the winner among the health startups participating in the II Innovation Forum? It is a very important recognition, especially because it comes from the public-private ecosystem and leading companies in the sector. For us, it validates three things: the relevance of the problem we address, the maturity of our solution, and its real applicability in both clinical and research settings. Furthermore, it represents an opportunity to accelerate collaborations with organizations and advance towards broader implementation in the health system. What are your main business objectives in the short and medium term? In the short term, our goal is to consolidate deployments in hospitals and mental health provider centers and expand the use of the platform in different clinical cases, strengthening impact evidence. We also want to continue promoting its use in clinical and academic research, generating new predictive models and scientific evidence. In the medium term, we aim to scale in Europe, advance in certification as a higher-level medical device, and position ourselves as a standard in mental health monitoring and prediction. What learnings would you highlight from your participation in the innovation forum? The main learning has been the importance of the real fit between problem and solution from the perspective of leading companies. The forum allows rapid validation of what is a priority for the healthcare system: integration, scalability, clinical evidence, and real implementation capacity. I would also highlight the value of the open innovation format, which facilitates very concrete conversations aimed at collaboration in both care and research. What do you consider being part of the startup and innovation ecosystem of the Madrid Community has contributed to you? The Madrid Community has a very strong ecosystem in health, research, and technology, and for us it has been key in our development. eB2 was born as a spin-off from Carlos III University of Madrid, and growing within this environment has allowed us to combine high-level research with real clinical application. Being part of this ecosystem has facilitated collaboration with hospitals, research centers, and other key actors, accelerating both development and clinical and scientific validation of the technology. Additionally, initiatives like RETECH-Madrid Community help connect innovation with real needs of the healthcare system, which is essential for bringing solutions like ours to market. Looking ahead, what milestones or key developments do you expect to achieve? Our next milestones are focused on three areas: First, expanding deployments in health systems and demonstrating impact at large scale. Second, advancing regulatory certification and clinical validation in new use cases. And third, continuing to develop artificial intelligence capabilities and evidence generation through clinical research. Our goal is to contribute to a paradigm shift: a more preventive, personalized, and data-driven mental health. Digital Entrepreneurship Networks. Digital Entrepreneurship Networks in the Madrid Community is a project led by the Madrid Community, through the Ministry of Digitalization, within the framework of the RETECH project (Territorial Networks of Technological Specialization) and funded by European NextGenerationEU funds under the Recovery, Transformation, and Resilience Plan. Investment Guide 2025 National report on tech and innovative companies.